Ivabradina Bluepharma

Ivabradine, the active ingredient in Ivabradina Bluepharma, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction, helping to lower heart rate without reducing contractility.

GNH USA supplies Ivabradina Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Bluepharma acts on the cardiac If current to manage angina and heart‑failure syndromes.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalisations.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Persistent visual loss. - Allergic reactions (rash, angioedema). - Elevated hepatic enzymes.

Before initiating therapy, clinicians should consider several safety aspects.

- Cardiac monitoring: patients with baseline heart rate <60 bpm should be observed. - Concomitant beta‑blocker use: may cause excessive bradycardia. - CYP3A4 inhibitors: avoid strong inhibitors or adjust dose. - Renal impairment: use with caution; dose may need adjustment. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Concomitant bradycardic agents (e.g., beta‑blockers, digoxin): risk of severe bradycardia. - Other If channel inhibitors: additive heart‑rate lowering effect.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may raise plasma levels. - QT‑prolonging drugs: monitor ECG for arrhythmia risk. - Alcohol: can enhance bradycardic effect.